Burning Rock presents three lung cancer studies at WCLC 2026
Burning Rock presented three studies at the 2026 World Conference on Lung Cancer in Seoul on Sept. 15, 2026.
Data addressed small invasive lung adenocarcinoma biology, response prediction for neoadjuvant immunochemotherapy in lung squamous cell carcinoma.
Separate work evaluated pleural effusion-based molecular testing in advanced lung cancer, highlighting specimen options for precision oncology workflows.
Studies used the company’s OncoScreen and OncoCompass platforms to support treatment stratification and molecular testing decisions.
BNR•
